Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
IPO Year: 1995
Exchange: NASDAQ
Website: myriad.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $32.00 | Equal-Weight | Morgan Stanley |
| 8/28/2024 | $35.00 | Overweight | Wells Fargo |
| 6/27/2024 | $29.00 | Sector Outperform | Scotiabank |
| 6/3/2024 | $20.00 | Underperform | Jefferies |
| 5/8/2024 | $25.00 → $35.00 | Market Perform → Outperform | Leerink Partners |
| 12/21/2023 | $23.00 | Neutral | Piper Sandler |
| 12/19/2023 | $20.00 | Equal Weight | Wells Fargo |
| 12/14/2023 | $23.00 | Buy | Guggenheim |
| 12/13/2023 | $28.00 | Outperform | Wolfe Research |
| 7/5/2023 | $18.00 | Underweight | JP Morgan |
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
10-Q - MYRIAD GENETICS INC (0000899923) (Filer)
8-K - MYRIAD GENETICS INC (0000899923) (Filer)
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. "We are pleased to expand o
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. "Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would ask them to come back two weeks later to do a Prequel screen. Now that Prequel can be performed at eight weeks, patients have the opportunity to complete all baseline lab work during that initial care
SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, continues to empower parents with increased access to prenatal testing. SneakPeek, the #1 OBGYN-recommended gender test with over 99% accuracy,[1] is now available over the counter in more than 8,800 retail locations nationwide. The product is the first of its kind to be sold on shelf in Walmart stores greatly expanding access for expectant parents who want to learn if they're having a girl or boy at-home as early as six weeks into pregnancy. According to a 2024 consumer survey, 82% of expectant parents want to know the baby's sex before delivery, a
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a
SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations. The collaboration combines the strengths of Myriad's high-quality hereditary cancer and reproductive genetics products, MyRisk® with RiskScore® and Foresight® Carrier Screen, with jscreen's trusted education and genetic care navigation program. Through the partnership, the jscreen program intends to reach hundreds of thousands of high-risk adults across the United States
Myriad's MyRisk® test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of point of care solutions in oncology. This collaboration allows physicians to order Myriad's MyRisk® Hereditary Cancer Test and view the results of the test directly in Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR®. MyRisk is the first hereditary cancer test to be incorporated into Flatiron's OncoEMR. The i
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations to study the use of molecular residual disease (MRD) testing in breast cancer using Myriad's Precise® MRD test. Research collaborations include: A study to determine whether circulating tumor DNA (ctDNA) level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery, led by Bora Lim, MD, at The University of Texas MD Anderson Cancer Center.A study t
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco. The low-cost and low-error sequencing achievable on the UG 100 may benefit several of
During the last three months, 4 analysts shared their evaluations of Myriad Genetics (NASDAQ:MYGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 1 1 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 1 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 15.08% increase, the current average ha
Scotiabank analyst Sung Ji Nam initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sector Outperform rating and announces Price Target of $29.
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions.
Jefferies analyst Tycho Peterson assumes Myriad Genetics (NASDAQ:MYGN) with a Underperform rating and lowers Price Target of $20.
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.Guidelines currently recommend adding ADT to RT in certain patients with localized prostate cancer. While ADT can be effective at slowing the progression of prostate cancer, it
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
4 - MYRIAD GENETICS INC (0000899923) (Issuer)
Morgan Stanley initiated coverage of Myriad Genetics with a rating of Equal-Weight and set a new price target of $32.00
Wells Fargo initiated coverage of Myriad Genetics with a rating of Overweight and set a new price target of $35.00
Scotiabank initiated coverage of Myriad Genetics with a rating of Sector Outperform and set a new price target of $29.00
Jefferies resumed coverage of Myriad Genetics with a rating of Underperform and set a new price target of $20.00
Leerink Partners upgraded Myriad Genetics from Market Perform to Outperform and set a new price target of $35.00 from $25.00 previously
Piper Sandler resumed coverage of Myriad Genetics with a rating of Neutral and set a new price target of $23.00
Wells Fargo initiated coverage of Myriad Genetics with a rating of Equal Weight and set a new price target of $20.00
Guggenheim initiated coverage of Myriad Genetics with a rating of Buy and set a new price target of $23.00
Wolfe Research initiated coverage of Myriad Genetics with a rating of Outperform and set a new price target of $28.00
JP Morgan resumed coverage of Myriad Genetics with a rating of Underweight and set a new price target of $18.00
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024. Fox brings nearly two decades of legal experience in the life sciences sector. Her expertise spans intellectual property, litigation, and regulatory matters, gained through roles in both in-house and private practice settings at industry-leading companies. As Chief Legal Officer, Fox's responsibilities will encompass a wide range of areas, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquis
SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women's health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience rooted in genetics and obstetrics/gynecology to Myriad. In her new role, she will support internal and external efforts to increase access to, and equity around, genetic testing throughout a woman's health journey including family planning, pregnancy management and hereditary cancer risk assessment. "We're thrilled to welcome Dallas
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad's oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombinat
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. Riggsbee will continue as a strategic advisor through March 31, 2024, to ensure a smooth transition. Riggsbee joined Myriad in 2014 as CFO. During his nine-year tenure, he has made significant contributions to Myriad's growth strategy and business transformation. In 2020, he served for six months as Myriad's interim CEO, navigating the business and supporting teammates thro
SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023. Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in life sciences and molecular diagnostics, to the team at Myriad Genetics. In his role as COO, he will be responsible for driving the company's lab operations, customer service initiatives, and product development innovations. "Sam is an accomplished leader who understands how to build teams and drive a patient-centric cultur
SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Pamela Wong as its new Chief Legal Officer. In her role, she is responsible for leading the company's legal function, including support and counsel for all legal affairs, intellectual property, patent protection, mergers and acquisitions, litigation, regulatory and quality assurance, compliance, and government affairs. As a legal executive and business leader with deep healthcare and legal expertise, Wong brings more than twenty years of experience spanning global IP portfolio development, management and enforcement,
SALT LAKE CITY, May 20, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Women's Health business. Gonzales has more than 20 years of women's health experience, most recently at Medela, a global leader in breast pumps and medical solutions, supporting millions of new moms and babies. She served as executive vice president of Medela Americas and helped position the company as the number one breast pump brand in the United States. Prior to Medela, Gonzales led commercial teams at Align Technology and Smith & Nephew. In her role at Myriad
Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Dennis H. Langer, M.D., J.D. to the Company's Board as an independent Director, effective May 1, 2021. Dr. Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies. He served as CEO of Neose Technologies, Inc., and was President of Dr. Reddy's North American business and was a Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a director of the Whitehead Institute for Biomedic
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor coverage and revenue cycle initiatives.Third quarter GAAP net loss improved to $22.1 million from a loss of $61.3 million in the third quarter of 2023 on improved revenue, gross margins and disciplined management of operating expenses. Third quarter adjusted EBITDA increased to $14.1 million from $1.4 million in third quarter of 2023.Third quarter GAAP loss per share improved to $(0.24) from $(0.75) in the third quarter of 2023; adjusted earnings (loss) per share improved to $0.06 from ($0.03) in the third quarter of 2023.Updated 2024 financial
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025. After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverag
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thursday, November 7, 2024 at 4:30 pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a
Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include
SALT LAKE CITY, July 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Tuesday, August 6, 2024 at 4:30pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the second quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a d
Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal (22%), Pharmacogenomics (21%), and Hereditary Cancer (16%). First quarter average revenue per test improved by 2% over the prior year period, reflecting no-pay reduction efforts.First quarter GAAP net loss of $26 million and positive adjusted EBITDA of $4 million; net loss and adjusted EBITDA improved significantly from $55 million and $(19) million, respectively, in the first quarter of 2023.First quarter GAAP earnings per share and adjusted earnings per share of $(0.29) and $(0.01), respectively, improved significantly as compared to $(0.67) and $(0.21), respectively, in the first quarter of 20
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-
SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To par
SALT LAKE CITY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the third quarter 2023. Conference Call and Webcast The dial-in number for domestic callers is 1-800-771-6781. International callers may dial 1-212-231-2900. All callers will be asked to reference reservation number 22028316. An archived replay
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on Thursday, Aug. 3, 2023 at 4:30 p.m. ET. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the period ending June 30, 2023. Conference Call and WebcastThe dial-in number for domestic callers is 1-800-954-0653. International callers may dial 1-212-231-2921. All callers will be asked to reference reservation number 22027563. An archived rep